Almirall's internationalisation process continues with its arrival in
the 8th largest pharmaceutical market
Respiratory and dermatology are key therapeutic areas for future growth
Aclidinium will be co-promoted with Forest
BARCELONA, Sept. 5, 2012 /CNW/ - Almirall S.A. (ALM.MC) announced the
opening of a new affiliate in Canada establishing direct presence in
the North American territory for the first time. The affiliate is
located in Toronto, an area highly regarded for its biopharmaceutical
"Almirall will now have the opportunity to make directly available to
Canadian patients a range of innovative medicines, especially in the
respiratory and dermatology fields," Eduardo Sanchiz, Chief Executive
Officer at Almirall, announces. "This is another milestone in our
internationalisation process: a substantial challenge that we take on
with enthusiasm," he adds.
In the Canadian pharmaceutical business (ranking as the 8th largest
globally), respiratory and dermatology are major markets. These are both key
therapeutic areas for Almirall too, and on which its R&D has a
Aclidinium - Almirall's recently approved drug for COPD in US and Europe
- will be one of the drugs rolled-out in Canada, where the Aclidinium
respiratory franchise will be co-promoted with Forest. Financial
details of the agreement have not been disclosed.
With the opening of its 13th affiliate, Almirall takes another step
further in its internationalisation process.
Aclidinium bromide inhalation powder is an anticholinergic indicated for
the long-term maintenance treatment of bronchospasm associated with
chronic obstructive pulmonary disease (COPD), including chronic
bronchitis and emphysema. When given by inhalation, aclidinium produces
bronchodilation by inhibiting the muscarinic M3 receptor in the airway
smooth muscle. Aclidinium is rapidly hydrolyzed in human plasma into
two major inactive metabolites.
It is administered using a multiple-dose dry powder inhaler. The inhaler
has a colored control window and audible "click" which confirm
successful inhalation of the dose and a dose indicator to let patients
know the approximate number of doses remaining in the inhaler.
Almirall has licensed US rights for Aclidinium to Forest Laboratories,
Inc., to Kyorin Pharmaceutical Co. Ltd for Japan and to Daewoong
Pharmaceutical Co. Ltd for Korea. Almirall has recently given rights of
joint commercialisation in the majority of European member states and a
number of non-EU countries to Menarini. Almirall maintains rights for
the rest of the world.
Almirall is an international pharmaceutical company based on innovation
and committed to health. Headquartered in Barcelona, it researches,
develops, manufactures and commercialises its own R&D and licensed
drugs with the aim of improving people's health and wellbeing. Almirall
focuses its research resources on respiratory, gastrointestinal,
dermatology and pain. Almirall's products are currently present in over
70 countries in the five continents. With the opening of the Canadian
affiliate, Almirall has now direct presence in Europe, Mexico and
Canada through 13 affiliates.
For further information please visit: http://www.almirall.com
IMS Knowledge Link, MAT/Q1 2012
For further information:
Media enquiries: Carolina Rodríguez, +34-91-788-32-00, email@example.com